featured
Outcomes of Imlunestrant, an Oral SERD, as Monotherapy and in Combination With Targeted Therapy in ER+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
J. Clin. Oncol 2024 Sep 06;[EPub Ahead of Print], KL Jhaveri, E Lim, R Jeselsohn, CX Ma, EP Hamilton, C Osborne, M Bhave, PA Kaufman, JT Beck, L Manso Sanchez, R Parajuli, HC Wang, JJ Tao, SA Im, K Harnden, K Yonemori, A Dhakal, P Neven, P Aftimos, J Yves-Pierga, YS Lu, T Larson, Y Jerez, K Sideras, J Sohn, SB Kim, C Saura, A Bardia, SL Sammons, F Bacchion, Y Li, E Yuen, ST Estrem, V Rodrik-Outmezguine, B Nguyen, R Ismail-Khan, L Smyth, M BeeramFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.